Menu ×


Pancreatic Adenocarcinoma Treatment Market Segmentation by Type (Chemotherapy, Targeted Therapy, and Others); by Affected Area (Exocrine, and Endocrine) – Global Demand Analysis & Opportunity Outlook 2030

  • Text Size:

Extensive insights into the Growth of Pancreatic Adenocarcinoma Treatment Market amidst COVID-19

Before we witness the stabilization of economic growth in Europe and North America, Asia Pacific is estimated to bounce back progressively with countries such as China, India, South Korea and Japan witnessing more opportunities to recover from the losses sustained during COVID-19.

Being the biggest market in Eastern Europe, Russia is estimated to take the lowest hit, offering a sigh of relief to the businesses operating in the country. Whereas, GCC is estimated to observe low investments due to the sliding prices of crude oil.

We evaluate the strategies and commitment of the Giant Players in the market towards creating products and services that customers value and rely on.

In an attempt to control and eliminate the surge of coronavirus cases and meet the demand for required medical devices along with providing efficient medical services, there is a drastic shift of investments from authoritative bodies towards the healthcare sector. Where the aftermath of this pandemic may take years to be measured, Research Nester estimates notable expansion of e-health, gaming, and media and entertainment industries till the whole situation is contained and the plan of action for the recovery process is determined. There is an estimated probability of the growth in businesses going back a year if the condition is controlled in the next 2-3 months.                                                         Request Insights

Read More


  • September 2020: Amgen Inc.’s new drug targeting KRAS mutations was approved by the U.S. Food and Drug Administration. This is the first ever therapy developed to treat KRAS cancers, which are often altered in colon, lung and pancreatic areas.

Global Pancreatic Adenocarcinoma Treatment Market Highlights 2022 – 2030

The global pancreatic adenocarcinoma treatment market is estimated to garner a large revenue and grow at a CAGR of ~7% over the forecast period, i.e., 2022 – 2030. The growth of the market can be attributed to the rising geriatric population around the world, increasing consumption of alcohol and smoking, and growing prevalence of obesity. According to the World Health Organization, 8.873 percent of the total population of the world was aged 65 years or above in 2018, which grew up to 9.318 percent in 2020. Along with these, escalating shift in the lifestyle of people and changing dietary preferences are also expected to boost the growth of the market in the forthcoming years. Furthermore, researchers and medical professionals all around the world are extensively being involved in developing innovative and more effective treatments for pancreatic cancer, which is a crucial factor projected to offer abundant growth opportunities to the market in the near future. CLICK TO DOWNLOAD SAMPLE REPORT


The market is segmented by type into chemotherapy, targeted therapy, and others, out of which, the targeted therapy segment is anticipated to hold the largest share in the global pancreatic adenocarcinoma treatment market on account of the growing introduction of new targeted therapies and biological therapies to minimize the after effects of existing therapies such as chemotherapy. In addition, on the basis of affected area, the exocrine segment is predicted to acquire the largest share during the forecast period, which can be credited to the fact that most of the types of pancreatic adenocarcinoma develop in exocrine. Apart from this, growing investments to study pancreatic adenocarcinoma treatment is also assessed to boost the growth of this market segment in the future.

Major Macro-Economic Indicators Impacting the Market Growth


According to the statistics by the World Health Organization, the global per capita healthcare expenditure amounted to USD 1,064.741 in the year 2017. The worldwide healthcare expenditure per person grew from USD 864.313 in 2008 to USD 1,110.841 in 2018, where the U.S. is the top country that amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018. As of 2018, the domestic general government healthcare spending in the U.S. was USD 5355.79, which grew from USD 3515.82 in 2008. These are some of the factors responsible for market growth over the past few years. Moreover, as per the projections by the Centers for Medicare & Medicaid Services (CMS), the estimated average annual percent change related to National Health Expenditures (NHE) in the U.S. was 5.2% in 2020 as compared to 2019 (4.5%). Furthermore, the National Health Expenditures are projected to reach USD 6,192.5 Billion in 2028, where the per capita expenditure is estimated to touch USD 17,611 in the same year. These are notable indicators that are anticipated to create lucrative business opportunities in upcoming years.

Global Pancreatic Adenocarcinoma Treatment Market Regional Synopsis

On the basis of geographical analysis, the global pancreatic adenocarcinoma treatment market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and the Middle East & Africa region. The market in the North America is estimated to gather the largest share over the forecast period on the back of well-established healthcare infrastructure, presence of large population suffering from the disease and increasing acceptance of pancreatic treatment procedure in the region. As per the National Cancer Institute, in 2021, 60,430 people in the United States are evaluated to suffer from pancreatic cancer. The total number of cases are predicted to rise by 3.2 percent since the previous year. In addition, strong presence of major market players is also expected to expand the region’s market in the upcoming years. Moreover, the market in Asia Pacific is projected to witness noteworthy growth during the forecast period, which can be ascribed to the rising occurrence of pancreatic adenocarcinoma and growing establishment of critical care centers in the region.

The global pancreatic adenocarcinoma treatment market is further classified on the basis of region as follows:

  • North America (U.S. & Canada) Market size, Y-O-Y growth & Opportunity Analysis
  • Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth & Opportunity Analysis
  • Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC, Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth & Opportunity Analysis
  • Asia-Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth & Opportunity Analysis
  • Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market size, Y-O-Y growth & Opportunity Analysis

Market Segmentation

Our in-depth analysis of the global pancreatic adenocarcinoma treatment market includes the following segments:

By Type

  • Chemotherapy
  • Targeted Therapy
  • Others

By Affected Area

  • Exocrine
  • Endocrine

Growth Drivers

  • Increasing Geriatric Population Around the World
  • Rising Prevalence of Obesity


  • Lack of Skilled Medical Professionals in Lower Economic Regions

Top Featured Companies Dominating the Market

  • Amgen Inc.
    • Company Overview
    • Business Strategy
    • Key Product Offerings
    • Financial Performance
    • Key Performance Indicators
    • Risk Analysis
    • Recent Development
    • Regional Presence
    • SWOT Analysis
  • F. Hoffman-La Roche AG
  • Novartis AG
  • Pfizer Inc.
  • Aduro Biotech Inc.
  • Clovis Oncology Inc.
  • Threshold Pharmaceuticals Inc.
  • NewLink Genetics Corp
  • Infinity Pharmaceuticals Inc.
  • Celgene Corporation


Related Reports

Disclaimer | Privacy Policy | Terms & Conditions

Copyright © 2021 Research Nester. All Rights Reserved